All In Biotech

Drug Trial Radar · NCT00514475

Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma

High-dose Therapy With Autologous Stem Cell Support in First Line Treatment of Mantle Cell Lymphoma- 90Y-Ibritumomab Tiuxetan in Combination With BEAM or BEAC to Improve Outcome for Patients Not in CR After Induction Treatment

Last checked: Nov 20, 2026Latest source record: May 4, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

160

Actual

Start

Nov 2005

Primary completion

Jun 2009

Study completion Jun 2009

Sponsor

Lead sponsor
Oslo University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 10, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine if outcome for patients with mantle cell lymphoma is improved by adding radioimmunotherapy to high-dose regimen before auto-transplant in patients who are not in CR after induction therapy.

Conditions

  • Mantle Cell Lymphoma

Interventions

  • 90Y-ibritumomab tiuxetan (Zevalin)Drug

    90Y-ibritumomab tiuxetan (Zevalin) at 0.4 mCi/kg is administered one week prior to start high-dose chemotherapy (BEAM/BEAC) in patients who have not achieved CR after induction therapy. Predosing with rituximab 250 mg/m2 one weeks prior to radioimmunotherapy and the same day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to treatment failure (TTF) for PR/CRu patients receiving Zevalin-BEAM/BEACTime frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Arne Kolstad

    Oslo, Oslo, Norway

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.